215
Participants
Start Date
February 13, 2017
Primary Completion Date
August 2, 2018
Study Completion Date
March 7, 2019
Columbia University Medical Center, New York
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Cleveland Clinic, Cleveland
Akron Children's Hospital, Akron
Neurology Department Hospital Universitari i Politecnic La Fe, Valencia
University Hospital of Bonn, Bonn
Dipartimento Ambientale di Neuroscienze, Roma
Baylor College of Medicine, Houston
The University of Texas Health Science Center, Houston
Children's Hospital Colorado, Aurora
Klinikim der Universitat Muchen, Friedrich-Baur Institute, Munich
University of Utah Hospital, Salt Lake City
University of California San Diego, La Jolla
Stanford Universtity, Palo Alto
Seattle Children's Hospital, Seattle
Azienda Ospedaliero Universitaria Policlinico G. Martino, Messina
Massachusetts General Hospital, Boston
The Children's Hospital of Philadelphia, Philadelphia
Calvary Health Care Bethlehem, Caulfield South
Royal North Shore Hospital, St Leonards
University of Calgary Metabolic Disease Clinica, Calgary
McMaster University Medical Center, Hamilton
Adult Metabolic Diseases Clinic, Vancouver
University of Copenhagen, Copenhagen
Institute of Genomic Medicine and Rare Disorders, Budapest
IRCCS Institute of Neurological Sciences of Bolgna, Bellaria Hospital, Bologna
ASST Spedali Civili di Brescia, Brescia
Istituto Nazionale Neurologico Carlo Besta, Milan
Ospedale Pediatrico Bambin Gesu, Roma
Hospital Universitario 12 de Octubre, Madrid
MRC Centre for Neuromuscular Diseases, London
Royal Victoria Infirmary, Newcastle upon Tyne
Istituto di Neurologia, Fondazione Policlinico Universitario A. Gemelli, Roma
Stealth BioTherapeutics Inc.
INDUSTRY